Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>HS TECH September 2026 had 1 ADD and 1 DELETE. With the first implementation week complete, we review current-cycle performance vs history.</li>
<li>Iluvatar Corex fell through the first implementation week after its bridge decline. The negative-bridge ADD pattern held, with a deeper fall than the historical average.</li>
<li>Tongcheng Travel also kept falling after implementation. The negative-bridge DELETE pattern held, and its decline was deeper than the historical average.</li>
</ul>


HS TECH September 2026 had 1 ADD and 1 DELETE. With the first implementation week complete, we review current-cycle performance vs history.
Iluvatar Corex fell through the first implementation week after its bridge decline. The negative-bridge ADD pattern held, with a deeper fall than the historical average.
Tongcheng Travel also kept falling after implementation. The negative-bridge DELETE pattern held, and its decline was deeper than the historical average.


HS TECH September 2026 Rebalance: Post-Implementation Review

Iluvatar CoreX

HS TECH September 2026 Rebalance: Post-Implementation Review